David J. Mazzo

Dr. David J. Mazzo is the President and Chief Executive Officer at Caladrius Biosciences.

Dr. Mazzo is a pharmaceutical executive and strategic leader with more than 35 years of broad international experience developing and launching drug products for both big pharma and emerging pharma in the U.S., Canada, Europe and Japan. He is also a seasoned board director, having served on the boards of all the companies for which he was CEO, as well as Essex Chemie AG (EU subsidiary of Schering-Plough), Avanir Pharmaceuticals and EyePoint Pharmaceuticals, where he served as chairman of the board until 2018. Dr. Mazzo is the current chairman of the board of Visioneering Technologies, Inc.

Dr. Mazzo earned a Ph.D. in Analytical Chemistry and an M.S. in Chemistry from the University of Massachusetts (Amherst), and he completed a research fellowship at the École Polytechnique Fédérale de Lausanne (Switzerland). He also holds a B.S. (Chemistry) and a B.A. (Honors – Interdisciplinary Humanities) from Villanova University (Pennsylvania).